- Home
- CELC vs ATRO Comparison
CELC vs ATRO Comparison
Compare CELC & ATRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELC | ATRO |
|---|---|---|
| Founded | 2011 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | CELC | ATRO |
|---|---|---|
| Price | $104.79 | $78.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $100.13 | $61.50 |
| AVG Volume (30 Days) | ★ 672.2K | 498.8K |
| Earning Date | 02-22-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.07 |
| Revenue Next Year | N/A | $12.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.58 | $19.41 |
| 52 Week High | $120.32 | $81.89 |
Technical Indicators
Market Signals| Indicator | CELC | ATRO |
|---|---|---|
| Relative Strength Index (RSI) | 48.10 | 59.89 |
| Support Level | $103.20 | $74.57 |
| Resistance Level | $109.75 | $81.25 |
| Average True Range (ATR) | 5.73 | 3.94 |
| MACD | -0.53 | -0.54 |
| Stochastic Oscillator | 47.16 | 57.77 |
Price Performance
Historical ComparisonAbout CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About ATRO Astronics Corporation
Astronics Corp supplies products to the aerospace, defense, and electronics industries. The company has two reportable segments namely Aerospace and Test Systems. The aerospace segment serves three primary markets: military, commercial transport, and General Aviation. The Test Systems segment serves the aerospace, defense, and semiconductor markets. The company generates a majority of its revenue from the Aerospace segment. Geographically, it generates a majority of its revenue from the United States.